Armstrong, A. W., Lebwohl, M., Bagel, J., Schlesinger, T., Banerjee, S., Kisa, R. M., Scharnitz, T., Hoyt, K., & Strober, B. (2023). Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in moderate to severe plaque psoriasis: efficacy by baseline body surface area (BSA) involvement and baseline Psoriasis Area and Severity Index (PASI). SKIN The Journal of Cutaneous Medicine, 7(2), s120. https://doi.org/10.25251/skin.7.supp.120